Francis deSouza was appointed CEO of Illumina in 2016 and is responsible for directing all
aspects of company strategy, planning, and operations. He initially joined the company as
President in 2013, and led Illumina’s business units and core functions responsible for
envisioning, developing and producing the company’s products.
Previously, deSouza served as President of Products and Services at Symantec Corporation, where
he was responsible for driving the vision for the company’s market-leading portfolio and served
in a variety of executive roles. He joined Symantec through the acquisition of IMlogic, where he
was co-founder and CEO.
Prior to joining IMlogic, deSouza was co-founder and CEO of Flash Communications, a provider of
corporate instant messaging that was acquired by Microsoft. Following the acquisition, he joined
Microsoft and led the team responsible for the development of the company’s enterprise real-time
collaboration offerings. Currently, he is a member of the board of directors for The Walt Disney
Francis deSouza received a BS and MS in Electrical Engineering and Computer Science from the
Massachusetts Institute of Technology.
Alex Aravanis, MD, PhD
Chief Technology Officer, Head of Research and Product Development
Alex Aravanis, MD, PhD, is Illumina’s Chief Technology Officer, Head of Research and Product
Development. He re-joined Illumina in June 2020 and is responsible for leading Illumina’s
research and product development teams in engineering, consumables, applications, user design,
software, informatics, and artificial intelligence. These teams are Illumina’s innovation engine
and deliver product excellence in next-generation sequencing platforms and applications to
accelerate scientific breakthroughs and translation of genomics to the clinic.
Alex is an experienced entrepreneur and was involved in founding several start-ups in the life
sciences and healthcare. Most recently, he co-founded GRAIL Bio where he served as Chief
Scientific Officer and Head of R&D. At GRAIL, Aravanis led the research, development,
operational, and clinical teams developing its multi-cancer early detection test. Alex’s passion
for accelerating the commercial application of technology innovation continue in his current
role where his responsibilities also include the Illumina Accelerator, the world’s first
business accelerator focused solely on creating an innovation ecosystem for the genomics
Prior to GRAIL, Alex served as Senior Director of R&D for Illumina, Inc., where he developed
multiple technologies, including clinical assays for the analysis of RNA and DNA from fixed
tissues, whole exome analysis, massively parallel single cell transcriptomics, and liquid biopsy
using cell-free nucleic acids.
Alex earned BS in Electrical Engineering, Computer Science, and Physics Minor from the University
of California, Berkeley, as well as an MS and PhD in Electrical Engineering, and an MD from
Stanford University. He holds more than 30 (pending and issued) patents and numerous
peer-reviewed publications, additionally he serves on various Scientific Advisor Boards for
Charles (Chuck) Dadswell is General Counsel of Illumina, where he has worldwide responsibility
for all legal and intellectual property matters and is also Illumina's code of ethics compliance
Before joining Illumina, Dadswell was Vice President, General Counsel for North and Latin America
and Corporate Director of Global Intellectual Property at bioMerieux. He was previously General
Counsel of BioDelivery Sciences International, a specialty pharmaceutical company, and oversaw
US intellectual property in a variety of positions with Glaxo, GlaxoWellcome and
Dadswell received an LL.M. in patent law and trade regulation from The George Washington
University Law School, a J.D. from Thomas M. Cooley Law School and a BS in Pharmacy from Ferris
General Manager—Europe, Middle East, & Africa
Paula Dowdy is the General Manager for Europe, Middle East and Africa. Since joining Illumina in
August 2016, Dowdy has reorganized the business, identified new markets and returned the region
to sustainable growth. In addition, Dowdy played a pivotal role as a senior leader with the
launch of the NovaSeq.
Previously, Dowdy was Senior Vice President for Cloud, Software, and Managed Services at Cisco
where she drove numerous innovative solutions. During her 20-year tenure at Cisco, she held
numerous leadership roles, spearheading product, software and service groups for virtually all
customer segments. Having spent the majority of her career in Europe, Dowdy currently resides in
Dowdy holds a Master of Business Administration from Pepperdine University and an undergraduate
degree from the University of California, Berkeley.
Chief People Officer
Aimee Hoyt is Chief People Officer at Illumina, where she is responsible for all aspects of the
company’s HR strategies. Hoyt has a successful track record for leading workforce
transformation, driving business growth and creating high-impact teams.
Previously, she has held senior positions at some of the world’s best-known technology companies
including Hewlett-Packard, Cisco and Sun Microsystems. Most recently, she was the Chief Human
Resources Officer at Rackspace, a leading managed cloud computing company, in San Antonio,
Texas. She led the HR team and was responsible for helping build, align and develop
high-performing global teams. During her tenure, Rackspace was recognized as one of Fortune’s
100 Best Companies to Work For, Top 30 Best Places in Tech and Great Places to Work for
Hoyt earned a master’s in human resource development from the Rochester Institute of Technology.
General Manager—Greater China
Li Qing is the General Manager for Greater China at Illumina. In his role, Qing is responsible
for leading and developing the commercial organization within China, which is a priority growth
region for Illumina. Qing oversees all aspects of Illumina’s growth strategy including
manufacturing, market development and access, medical and regulatory affairs, regional
marketing, competitive positioning, and product launches among others. Qing brings more than 25
years of unparalleled experience in leadership, business management and developing
organizations’ capabilities to strengthen market opportunities within the pharmaceutical and
life science industries. He has held numerous senior level positions for a number of global
companies including GE Healthcare, Baxter,Novartis, and Solvay.
Most recently Qing was General Manager for Life Sciences at GE Healthcare China. He led more than
five business units, covering four customer segments across mainland China, Taiwan, and Hong
Qing received an Executive MBA from the China Europe International Business School.
Chief Operations Officer
Bob Ragusa is Chief Operations Officer for Illumina where he is responsible for the company’s
operations serving clinical and research customers. His organization includes the global
Manufacturing, Clinical Lab Services, Supply Chain, Quality, Life Cycle Management, Information
Technology, and Global Facilities and Real Estate teams who are committed to ensure high product
quality and customer satisfaction.
Prior to joining Illumina, Ragusa was Executive Vice President of Engineering and Global
Operations at Accuray, a radiation oncology company, where he and his team were responsible for
the development, manufacturing and distribution of innovative precision treatment solutions.
Ragusa served as Senior Vice President of Global Operations for Applied Biosystems from 1997
Ragusa currently serves on the Board of Directors for Twist Biosciences. He holds a Bachelor of
Science in Electrical Engineering and a Master of Business Administration from the University of
Connecticut as well as a Master of Science in Biomedical and Electrical Engineering from
Carnegie Mellon University.
Chief Financial Officer
Sam Samad joined Illumina in 2017 and holds the role of Chief Financial Officer with
responsibility for the company’s finance, accounting, investor relations, internal audit,
treasury, and global information systems functions.
Before joining Illumina, Samad held several senior leadership positions at Cardinal Health
including Senior Vice President and Corporate Treasurer, leading all tax and treasury functions.
During his tenure as Treasurer, Samad also had operational and financial responsibility for
Cardinal Health’s China business. Prior to that, Samad served as Senior Vice President and Chief
Financial Officer for Cardinal Health’s $85B pharmaceutical segment, among other leadership
roles. Prior to Cardinal Health, Samad spent thirteen years at Eli Lilly and Company, in a
variety of sales and finance roles, both domestically and internationally, including his role as
Chief Financial Officer of the Canada affiliate prior to leaving Eli Lilly. Samad started his
career at Pepsico Inc.
Samad has served as Director on the Board for IDEXX Laboratories, Inc. (IDXX) since July 2019 and
on the Board of Visitors at the Owen Graduate School of Management since 2016.
Samad holds a BBA degree from the American University of Beirut in Lebanon and an MBA from
McMaster University in Hamilton, Canada.
Chief Commercial Officer
Susan Tousi is Chief Commercial Officer at Illumina, where she leads global sales, commercial
operations, and commercial strategy and enablement. Susan combines her extensive general
management leadership and deep technical knowledge of Illumina’s product portfolio to ensure the
global commercial success of the organization. She is committed to empowering Illumina customers
with innovations to further unlock the power of the genome.
Susan has been with Illumina since 2012, and previously lead the product development organization
as Chief Product Officer. During that time, she was responsible for global engineering,
consumables, sequencing applications, IVD, software and informatics development efforts: During
this time, she oversaw the most impactful decade of product launches including: HiSeq X,
NovaSeq, MiSeq Dx, NextSeq 550Dx/1000/2000, iSeq, VeriSeq NIPT, TSO500, COVIDSeq, DRAGEN™, and
Illumina Connected Analytics. Additionally, she led the acquisition of Edico Genomics, BlueBee,
and Enancio, combined with Illumina’s existing software solutions, these new capabilities enable
scalable, seamless, end-to-end software solutions that drive the utilization of genomic data and
accelerate the adoption of genomic data in clinical care.
Susan has more than 25 years of R&D and business leadership at Fortune 100 technology
companies and within the life sciences industry. Formerly, she was Corporate Vice President and
General Manager for Eastman Kodak’s Consumer Inkjet Systems organization. Prior to joining
Kodak, Susan was an R&D program manager for Phogenix Imaging LLC, a joint venture start-up
of Hewlett-Packard and Kodak. She previously spent 10 years with Hewlett-Packard in technical
and management roles. Along with many academic honors, she has received numerous awards in both
business and technology. In 2018, Susan was elected to the National Academy of Engineers. Susan
was named one of the 50 Top Diverse Leaders for 2020 by the California Diversity Council and is
a member of the International Women’s Forum, a global organization of preeminent women of
significant and diverse achievement.
Susan holds an MBA degree from UCLA and an Honors BS in Engineering Science and Mechanics from
Pennsylvania State University.
Susan serves as an executive trustee at the world renowned La Jolla Playhouse and on the UCSD
Jacobs School of Engineering Dean’s Council of Advisors.
General Manager—Asia Pacific & Japan
Gretchen Weightman is the General Manager for Asia Pacific and Japan at Illumina. In her role,
Weightman is responsible for leading and developing the commercial organization within the
region that includes Japan, Singapore, Australia, South Korea, New Zealand, and India.
Weightman has held several leadership positions within Illumina prior to her current role. She
was the Director of Sales for Asia Pacific, where she was responsible for sales of the Asia
Pacific region, overseeing five geographical districts for orders, shipments and revenue. Prior
to this, Weightman was the Senior Marketing Manager for South Asia Pacific, responsible for the
overall marketing strategy and implementation in South East Asia, India, Singapore, Australia,
and New Zealand.
Prior to joining Illumina, Weightman worked at Applied Biosystems in a variety of commercial
positions including Sales, Marketing, and Product Management. Her professional career started at
Genesis Research & Development where she set up the high-throughput sequencing facility.
Weightman graduated from Auckland University with a BSc in Molecular Genetics and a Diploma of
Joydeep Goswami, PhD
Chief Strategy and Corporate Development Officer
Joydeep Goswami is Chief Strategy and Corporate Development Officer where he
responsible for driving planning, strategic partnerships and acquisitions.
Most recently, he served as the President of Thermo Fisher Scientific’s Clinical Next-Generation
Sequencing (NGS) and Oncology business unit, where he oversaw efforts that drove the adoption of
NGS in clinical oncology, research and reproductive health. Goswami has held senior leadership
roles across the pharma/biotech, diagnostics and research tool continuum, previously serving at
companies such as Life Technologies and Invitrogen, in addition to Thermo Fisher Scientific. He
has led teams across various functions, including sales, marketing, R&D and other support
functions. Mr. Goswami served as President, Asia Pacific and Japan while at Thermo Fisher
Scientific and created the Stem Cells and Regenerative Medicine Business Unit at Invitrogen.
Additionally, he spent five years at McKinsey, where he specialized in strategy for
pharmaceutical, medical technology and technology companies.
Mr. Goswami holds his MS, PhD in Chemical Engineering, an MBA from MIT and a Bachelor’s degree in
Chemical Engineering from the Indian Institute of Technology.
Phil Febbo, MD
Chief Medical Officer
Phil Febbo, MD was appointed as Chief Medical Officer in March 2018. In this role, he is
responsible for developing and executing the Company’s medical strategy to drive genomic testing
into healthcare practice. Dr. Febbo has a successful track record of translational research,
clinical excellence, and for embedding molecular insights into clinical care.
Immediately before joining Illumina, Dr. Febbo served as CMO of Genomic Health. Prior to his five
years at Genomic Health, Dr. Febbo was a Professor of Medicine and Urology at the University of
California, San Francisco (UCSF), where his laboratory focused on using genomics to understand
the biology and clinical behavior of prostate cancer, and his clinical practice focused on
Before joining the faculty of UCSF as an associate professor in 2010, Dr. Febbo worked at Duke
University Medical Center’s Institute of Genome Sciences and Policy. He completed his internal
medicine residency at the Brigham and Women’s Hospital, and his fellowship in oncology at the
Dana-Farber Cancer Institute. After which he was an Attending Physician in the Genitourinary
Oncology Center at Dana-Farber, Instructor at Harvard Medical School, and a post-doctoral fellow
in Dr. Todd Golub's laboratory at Dana-Farber, as well as the Whitehead Institute Center for
Genomic Research of MIT (now the Broad Institute). Throughout his career, Dr. Febbo has served
as a primary investigator for the Translational Research Program of The Alliance, an
NCI-supported cooperative group, where his work focused on incorporating biomarkers into large
Dr. Febbo holds a Bachelor of Arts degree in Biology from Dartmouth College and an M.D. from
Nicole Berry is the General Manager for the Americas Region, inclusive of the U.S., Canada, and
Latin America. In this role, she is responsible for leading the customer facing functions
including Direct and Channel Partner Sales, Service and Support, and Regional Commercial
Operations teams in the Americas region.
Berry has been with Illumina since 2009 and has held several commercial leadership positions
within the company. During the three years prior to her current role, she served as the Vice
President of Sales for the Americas. Prior to this, Berry served in a number of sales management
roles covering the U.S. and Canada.
Prior to joining Illumina, Berry worked at Applied Biosystems on the U.S. sales management team.
Other highlights of her professional career include 15 years at Eastman Kodak Company, where she
held a variety of global marketing and business management roles. Her professional career
started at the Sloan Kettering Institute in the Tumor Immunogenetics laboratory of Dr. Lloyd
Berry graduated from the University of Rochester with a B.S. in Biology, with a concentration in
Chief Marketing Officer
Kathryne Reeves is Chief Marketing Officer at Illumina, where she is responsible for the
development and implementation of a global marketing strategy that strives to expand patient and
physician awareness of the benefits of genomic testing, amplify the voice of our customers, and
accelerate clinical adoption of genomics.
Reeves brings more than 25 years of cross-industry marketing and corporate strategy experience to
Illumina. Most recently, she was Senior Vice President of Enterprise Marketing and General
Manager of the Medical Services Global Business Unit at Cardinal Health, where she led a rapidly
growing portfolio of business with annual revenues in excess of $1 billion USD. Prior to
Cardinal Health, Reeves held positions at Booz Allen Hamilton, AOL/Time Warner, Nationwide
Insurance, and Scotts Miracle-Gro, among others.
Reeves is a member of the International Women’s Forum where she was a Leadership Fellow in 2017,
and was named one of the Top Influential Women in Corporate America by the Savoy Network in
2016. She holds a B.S. in Civil Engineering from Stanford University and an MBA from Harvard